IDEAYA Biosciences, Inc.
IDYA
$17.45
-$0.90-4.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 7.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 7.00M | -- | -- | -- |
| Cost of Revenue | 70.89M | 140.18M | 57.15M | 54.53M | 42.81M |
| Gross Profit | -70.89M | -133.18M | -57.15M | -54.53M | -42.81M |
| SG&A Expenses | 13.50M | 10.96M | 9.74M | 10.39M | 8.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.39M | 151.14M | 66.89M | 64.93M | 51.02M |
| Operating Income | -84.39M | -144.14M | -66.89M | -64.93M | -51.02M |
| Income Before Tax | -72.18M | -130.31M | -51.82M | -52.77M | -39.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.18M | -130.31M | -51.82M | -52.77M | -39.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.18M | -130.31M | -51.82M | -52.77M | -39.57M |
| EBIT | -84.39M | -144.14M | -66.89M | -64.93M | -51.02M |
| EBITDA | -83.79M | -143.57M | -66.32M | -64.31M | -50.40M |
| EPS Basic | -0.82 | -1.49 | -0.60 | -0.68 | -0.53 |
| Normalized Basic EPS | -0.51 | -1.10 | -0.38 | -0.42 | -0.33 |
| EPS Diluted | -0.82 | -1.49 | -0.60 | -0.68 | -0.53 |
| Normalized Diluted EPS | -0.51 | -1.10 | -0.38 | -0.42 | -0.33 |
| Average Basic Shares Outstanding | 88.36M | 87.34M | 86.19M | 77.96M | 75.11M |
| Average Diluted Shares Outstanding | 88.36M | 87.34M | 86.19M | 77.96M | 75.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |